Environment-friendly electric vehicles are yet to become popular in Bangladesh due to a lack of facilities and high import ...

Republic Day 2026: Indian Army's animal contingent makes historic debut at Kartavya Path, steals spotlight Toyota Urban Cruiser Ebella launched: Check price, features, design, battery, booking date ...

Mr Alex Pretti, a 37-year-old ICU nurse, was fatally shot on Jan 24 by ICE agents. Read more at straitstimes.com. Read more ...

DelveInsight's Cystinosis Market Insights report includes a comprehensive understanding of current treatment practices, cystinosis emerging drugs, market share of individual therapies, and current and ...

Solid-state advancements and circular recycling ecosystems will drive future growth, projected to double energy density by 2030. These innovations will slash material costs by 30%, securing supply ...

This video focuses on restoring lost performance from the team’s Jaguar after issues reduced its output. It shows testing, adjustments, and mechanical fixes designed to bring the car back to proper ...

View post: This ‘Very Bright’ LED Work Light Is on Sale for Only $20 at Target Kei cars are affordable, fuel-efficient, and offer unique urban-friendly features for U.S. buyers. Models like the Nissan ...

Sports cars are famously undefinable, encompassing a broad array of roadsters, four-door cars, coupes, grand tourers, supercars, and even some straight-up race cars. Power, or lack thereof, is not a ...

Techtronic Industries will invest $120 million to relocate its floor care headquarters from North Carolina to Anderson, South Carolina. The move is expected to create 120 new jobs and will consolidate ...

One item to point out is that Tvardi Therapeutics (TVRD) brought its pipeline forth to public trading because of a merger it enacted with Cara Therapeutics and thus was able to list on the NASDAQ. At ...

Tivardi Therapeutics (NASDAQ:TVRD) is down ~85% in Monday trading after reporting that preliminary results from a phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis showed significantly higher ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...